Akebia Therapeutics Inc (NASDAQ: AKBA) is 106.32% higher on its value in year-to-date trading and has touched a low of $0.80 and a high of $4.08 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $3.83 in the last trading session, with the day’s gains setting it 0.09%.
Currently trading at $3.92, the stock is 26.74% and 56.60% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.83 million and changing 2.35% at the moment leaves the stock 98.43% off its SMA200. AKBA registered 266.36% gain for a year compared to 6-month gain of 94.06%. The firm has a 50-day simple moving average (SMA 50) of $2.5032 and a 200-day simple moving average (SMA200) of $1.975475.
The stock witnessed a 53.73% loss in the last 1 month and extending the period to 3 months gives it a 103.11%, and is 14.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.47% over the week and 3.32% over the month.
Akebia Therapeutics Inc (AKBA) has around 181 employees, a market worth around $1.03B and $184.91M in sales. Fwd P/E is 52.97. Profit margin for the company is -24.51%. Distance from 52-week low is 390.00% and -3.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.93%).
The EPS is expected to grow by 80.61% this year.
Akebia Therapeutics Inc (AKBA) Top Institutional Holders
187.0 institutions hold shares in Akebia Therapeutics Inc (AKBA), with institutional investors hold 40.29% of the company’s shares. The shares outstanding are 261.64M, and float is at 251.87M with Short Float at 7.83%. Institutions hold 38.88% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 11.64 million shares valued at $11.87 million. The investor’s holdings represent 5.5499% of the AKBA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.28 million shares valued at $9.46 million to account for 4.4235 of the shares outstanding. The other top investors are ALERCE INVESTMENT MANAGEMENT, L.P. which holds 5.75 million shares representing 2.7409% and valued at over $5.86 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.1632 of the shares totaling 4.54 million with a market value of $4.63 million.
Akebia Therapeutics Inc (AKBA) Insider Activity
The most recent transaction is an insider sale by Malabre Richard C, the company’s SVP, Chief Accounting Officer. SEC filings show that Malabre Richard C sold 13,334 shares of the company’s common stock on Jun 04 ’25 at a price of $3.53 per share for a total of $47069.0. Following the sale, the insider now owns 0.27 million shares.
Akebia Therapeutics Inc disclosed in a document filed with the SEC on Mar 03 ’25 that Butler John P. (CEO and President) sold a total of 46,409 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $1.83 per share for $84928.0. Following the transaction, the insider now directly holds 2.56 million shares of the AKBA stock.
Still, SEC filings show that on Mar 03 ’25, Burke Steven Keith (SVP, Chief Medical Officer) disposed off 7,144 shares at an average price of $1.83 for $13074.0. The insider now directly holds 809,090 shares of Akebia Therapeutics Inc (AKBA).
